NEW YORK (GenomeWeb News) – After just day one day at the UBS Global Life Sciences Conference in New York it is clear that life science tools firms and investors alike remain very interested in the fast-growing molecular diagnostic market.
With a variety of companies pegging the global molecular diagnostics market currently at around $3 billion, conference speakers were eager to show off their current offerings and future plans for the market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.